RxDoctor Payments Data

Cherif Boutros, MD

Surgical Oncology · Englewood, NJNPI 1912105495

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 94.6% of the total across 46 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 13.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $411 and has fallen 66.1% since, to $139 in 2025.

$1,270in general payments, 2019–2025

Across 46 payments — averaging $27.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Galvanize Therapeutics, Inc$177
  • Eisai Inc.$158
  • AstraZeneca$147
  • Exelixis Inc.$137
  • Merck$128
  • Pharmacyclics LLC, An Abbvie Company$104
  • plus $419 from 12 others

What the payments were for

  • Food & beverage$1,20295%
  • Education$685%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,270 in reported general payments places this provider in the 55th percentile of 59 surgical oncology providers in New Jersey.

See all surgical oncology providers in New Jersey

Medicare billing

Part B allowed, 2024
$60,429
Medicare patients
93
Services billed
158

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other surgical oncology in Englewood

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →